Laboratory of targeted gene mapping for predictive oncological diagnostics of Czech Center Digital Genomics (Q11526): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed label, description and/or aliases in 2 languages: Changing unique label-description pair)
(‎Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement)
Property / financed by
 
Property / financed by: Directorate-General for Regional and Urban Policy / rank
Normal rank
 

Revision as of 15:53, 28 October 2020

Project Q11526 in Czech Republic
Language Label Description Also known as
English
Laboratory of targeted gene mapping for predictive oncological diagnostics of Czech Center Digital Genomics
Project Q11526 in Czech Republic

    Statements

    0 references
    0 references
    25,300,500.0 Czech koruna
    0 references
    1,012,020.0 Euro
    10 January 2020
    0 references
    50,601,000.0 Czech koruna
    0 references
    2,024,040.0 Euro
    10 January 2020
    0 references
    50 percent
    0 references
    31 March 2020
    0 references
    Institute of Applied Biotechnologies a.s.
    0 references

    50°5'1.93"N, 14°30'28.48"E
    0 references
    10800
    0 references
    10800
    0 references
    Záměrem projektu TGM je vytvoření nového pracoviště pro cílené mapování lidského genomu, které bude sloužit k kolaborativnímu vývoji a klinickému výzkumu nových produktů pro stanovení ranných stádií rakoviny s využitím cirkulujících buněk z krve. Plánujeme zásadním způsobem přispět k rozvoji Theranostiky v ČR, tedy terapie založené na diagnostice, která vede k personalizaci zdravotní péče, zvýšení efektivity a cílené terapie a výrazně snižuje léčebné náklady. a. (Czech)
    0 references
    The aim of the TGM project is to create a new workplace for targeted mapping of the human genome, which will serve for collaborative development and clinical research of new products for the determination of early stages of cancer using circulating cells from blood. We plan to make a major contribution to the development of Theranostka in the Czech Republic, i.e. diagnostic therapy, which leads to personalisation of health care, increased efficiency and targeted therapy and significantly reduces medical costs. a. (English)
    22 October 2020
    0 references

    Identifiers

    CZ.01.1.02/0.0/0.0/17_093/0012409
    0 references